Exosomes dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
In 110 people with diabetes foot sores, sores treated with exosomes healed in about 6 weeks, against about 20 weeks without them. What clinics sell is almost never that product. The field even had to write a rulebook, because scientists could not agree on how to describe what they were studying.
Evidence grade for Exosomes: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 1 completed trial, 110 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 110
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 110 people given it
2 effects reported, 2 unwanted, by people using it, not a trial
Goal pages: Skin, hair and appearance
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Exosomes are tiny bubbles that cells send out. They carry messages from one cell to another. Clinics sell exosomes made from stem cells for skin, hair, joints and drips. No exosome product is approved anywhere. What is in a clinic vial is not checked by anyone.
What people take it for
- Faster healing of wounds and injuries.
- Thicker hair.
- Better looking skin after a facial.
- Joint pain, as a shot into the joint.
What studies in people showed
There is one good study in people. 110 people had diabetes foot sores that would not heal. Sores treated with an exosome product each week healed in about 6 weeks on average. The others took about 20 weeks. That study used one product, on one kind of wound, for four weeks. For hair loss there is only a review of early studies, and it is thin. Nobody has tested the drips, facials or joint shots sold in clinics. The field even wrote a rulebook, because scientists could not agree on how to describe what they were studying.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- The page's main safety worry is germs. This is a living-cell product, and one made outside an approved factory can carry them.
- Nobody can tell you the dose or what is inside a clinic vial, because nobody has measured it.
Where these come from: The healing numbers are from the one foot sore study on this page. The safety points come from the reviews on this page. We have no forum or clinic reports for this one.
My bottom line
The foot sore result is real, and I hope this turns into medicine. But the vial in a clinic is not the thing that was tested, and nobody can tell you what is in it. I would not pay for it or put it in my body.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 4 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is Exosomes?
In 110 people with diabetes foot sores, sores treated with exosomes healed in about 6 weeks, against about 20 weeks without them. What clinics sell is almost never that product. The field even had to write a rulebook, because scientists could not agree on how to describe what they were studying.
Exosomes are tiny bubbles that cells send out to other cells. Each bubble carries proteins and genetic messages. That part is real biology, and nobody disputes it. The sales pitch is simple. Collect the bubbles that stem cells give off, and use those instead of the cells.
There is one good result in real people. 110 people had diabetes foot sores that would not heal. They were split into three groups. One group got exosomes on the sore each week, plus normal wound care. One got normal care alone. One got normal care plus the same liquid with no exosomes in it. The exosome group healed in about 6 weeks on average. The others took about 20 weeks.
The problem is everything else. An exosome product is not one thing. What is inside the bubbles depends on which cells made them, how those cells were grown and how the bubbles were collected. The field wrote a rulebook because scientists could not describe their own samples the same way. So one good result with one product on one kind of sore tells you very little about a vial in a clinic.
How does Exosomes work?
Exosomes are very small bubbles, about 30 to 150 nanometres across. Cells build them inside and then push them out. Each one carries proteins, fats and genetic messages to other cells, and those messages can change what the other cell does. For treatment, the cargo is the real drug, not the bubble. Any effect on wounds, swelling or repair comes from what the bubble carries. That cargo depends on which cells made it and how they were grown. Two products with the same size and count can carry totally different cargo. Nothing on the label tells you which one you have.
What have studies in people found about Exosomes?
One well-run study in people with a strong result, for one product used one way. A thin set of studies on skin and hair. And a big market running far ahead of both.
- 110 people with diabetes foot sores that would not heal: sores treated with exosomes plus normal care healed in about 6 weeks on average, against about 20 weeks for the others. More people in the exosome group healed fully.
- That study also had a group that got the same liquid with no exosomes in it. That matters, because the liquid alone can affect a wound, and most studies in this field skip that check.
- For hair loss, where most people first meet these products, there is only a review of early studies. It is much thinner than the ads suggest.
- No exosome product is approved anywhere, for anything.
- The field wrote a rulebook because labs could not describe or compare their samples the same way.
- A look at businesses that sell straight to the public found claims about approval that do not hold up, since nothing is approved.
What this does not tell you: The strong result is one study. It ran for four weeks. It used one product, from one source, put on one kind of wound. None of that carries over to a drip, a facial, a joint shot or a scalp treatment. None of it carries over to a different product either. Nothing is approved, and there is no standard way to describe these products. So a clinic cannot tell you the dose, the strength or what is inside. Mostly, nobody has measured it. No study also means no safety data. Germs are a real worry with a living-cell product made outside an approved factory.
The state of the research
This page is tougher on the whole category than on the one study, and here is why.
The foot sore study is good work. It had three groups, including one that got the liquid with nothing in it. It measured something that matters to patients, and the effect was big. If exosome treatment becomes real medicine, studies like that are how it will happen. The biology behind it is sound.
But the gap between that study and what is sold is the widest on this site. Most pages here have a promising idea and no study. Here there is a study, but the product tested is not the product sold. What an exosome does depends on its cargo. The cargo depends on the cells and how they were grown. The field needed a rulebook just to agree on how to describe any of it. So when a clinic offers exosomes, the word names a kind of particle, not a product with known contents.
So the simple question, does this work, has no answer for the whole category. It has an answer for one product put on diabetes foot sores. It has no answer at all for the drip or facial being sold. That includes safety. A living-cell product made outside an approved factory can carry germs, and no amount of good biology makes that risk go away.
The evidence, in charts
Fig. 1a · how many people
110people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| Stem Cell Research and Therapy 2025 | 110 | 100% |
The whole total is one study of 110. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
1 of 4 sources here is a study in people. The rest are not.
- Study in people · done in people125%
- Review of studies · sums up other studies375%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 3 different years, 2023 to 2025, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- Not applicable. These are vesicles rather than molecules, generally 30 to 150 nanometres in diameter.
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Not meaningfully described. Systemically administered vesicles are cleared from circulation within minutes to hours, mostly by liver and spleen, which is one reason the strongest human evidence involves local application rather than infusion.
No amino acid sequence is on file for Exosomes, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2025The transforming role of Wharton's jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial
In 110 people with diabetes foot sores that would not heal, exosomes put on the sore each week, plus normal care, made sores heal faster. They healed in about 6 weeks on average, against about 20 weeks for the others. More of the exosome group healed fully. One comparison group got the same liquid with no exosomes in it, which is a better check than most studies in this field use.
110 patients with chronic diabetic foot ulcers randomised to three arms: weekly topical Wharton's jelly mesenchymal stem cell exosomes plus standard of care, standard of care alone, or standard of care plus the exosome vehicle, over four weeks. 53 patients (62%) fully recovered by the end of the study, significantly more in the treated group than in controls. Mean time to full recovery was 6 weeks in the treated group (range 4 to 8) against 20 weeks in controls (range 12 to 28). Including a vehicle arm is the right design and is unusual in this field.
- Review of studies2024Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches
The field's own rulebook for how to describe these tiny bubbles. It exists because labs could not describe or compare their samples the same way. If scientists need a rulebook to say what they are studying, a clinic cannot tell you what is in a vial.
The field's own standards document, and the single most important citation on this page. It exists because researchers could not consistently describe, characterise or compare the vesicle preparations they were studying. A discipline that needs a consensus document defining what counts as its object of study is not a discipline where a clinic can credibly tell you what is in a vial.
- Review of studies2025Exosomes for treating hair loss: a review of clinical studies
A review of the studies on exosomes for hair loss, the use most people see in ads. The studies are much thinner than the marketing.
A review of the clinical studies behind one of the most heavily marketed cosmetic uses. Relevant because hair loss is where most consumers first encounter an exosome product, and the clinical literature behind it is much thinner than the marketing.
- Review of studies2023Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies
A look at what US businesses that sell stem cell and exosome treatments straight to the public say about approval. Useful if a clinic told you its product is approved. Nothing is.
An analysis of what businesses selling these therapies directly to consumers actually claim about their regulatory status. The commercial reality check for anyone who has been told in a clinic that a product is approved, registered or FDA-compliant.
Common questions
Has Exosomes been tested in people?
Yes. 110 people given it across 1 completed trial cited here, 0 of which found nothing. In 110 people with diabetes foot sores, sores treated with exosomes healed in about 6 weeks, against about 20 weeks without them. What clinics sell is almost never that product. The field even had to write a rulebook, because scientists could not agree on how to describe what they were studying.
What is the Exosomes dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 110 people given it
Is Exosomes FDA-approved?
No exosome product is approved by the FDA for any use. The FDA has said publicly that there are no approved exosome products, and it has acted against clinics selling them. So anything sold in a clinic is unapproved, whatever it is called.
Do exosomes work?
For one product, put on the skin, for diabetes foot sores that would not heal, yes. In 110 people, treated sores healed in about 6 weeks on average, against 20 weeks for the others. For anything else being sold, nobody knows. What an exosome does depends on what it carries, and no two products are the same.
Why can you not just say whether the category works?
Because it is not one substance. It is a mix of tiny bubbles, and what is inside depends on which cells made them and how those cells were grown. The field wrote a rulebook because scientists could not describe or compare their samples the same way. A good result for one product tells you very little about another.
Is the exosome treatment my clinic offers approved?
No. No exosome product is approved for any use in the United States, the United Kingdom, Australia or Canada. If a clinic told you otherwise, researchers have looked at exactly that. One study checked the approval claims these businesses make when they sell straight to the public.
Are they safe?
Nobody knows, and the risk is more real here than for most things on this site. This is a living-cell product. One made outside an approved factory can carry germs, on top of the unknown effects of unknown cargo. No studies means no safety data. It does not mean it is safe.
What about exosomes for hair loss?
That is where most people first meet exosomes, and the studies are much thinner than the ads. A 2025 review looked at the studies that exist. It covers a new area and does not settle anything. The same problem applies too: the product in the clinic is not the product in the study.